TABLE 2.
PK parameter estimates for patients from ALTA‐1L and ALTA based on the population PK model
| Parameter | Geometric mean (5th and 95th percentiles of distribution) | |
|---|---|---|
| ALTA−1L (n = 123) | ALTA (n = 201) | |
| CL/F, L/h | 8.45 (4.04, 17.8) | 9.90 (4.06, 23.0) |
| V1/F, L | 160 (69.0, 302) | 199 (86.0, 468) |
| Q2/F, L/h | 12.6 (12.6, 12.6) | 12.6 (12.6, 12.6) |
| V2/F, L | 118 (46.5, 283) | 124 (78.3, 259) |
| Q3/F, L/h | 2.67 (2.67, 2.67) | 2.67 (2.67, 2.67) |
| V3/F, L | 78.5 (78.5, 78.5) | 78.5 (78.5, 78.5) |
| Transit compartments, n | 2.76 (1.71, 5.37) | 2.72 (1.85, 4.46) |
| Mean transit time, h | 1.01 (0.538, 2.36) | 0.998 (0.584, 1.92) |
| Albumin covariate effect on CL/F | 1.03 (0.874, 1.13) | 0.939 (0.758, 1.09) |
Abbreviations: ALTA‐1L, Anaplastic Lymphoma Kinase in Lung Cancer Trial of brigAtinib in First Line; CL/F, apparent oral clearance from the central compartment; PK, pharmacokinetic; Q2/F, intercompartmental clearance between the central and first peripheral compartments; Q3/F, intercompartmental clearance between the central and second peripheral compartments; V1/F, apparent central volume of distribution; V2/F, apparent volume of distribution of the first peripheral compartment; V3/F, apparent volume of distribution of the second peripheral compartment.